Adagio Medical (Nasdaq:ADGM) announced today that it submitted its premarket approval (PMA) application to the FDA for its ...

The application draws on data from the FULCRUM-VT pivotal IDE trial, which enrolled 209 patients across 20 centres.

Please provide your email address to receive an email when new articles are posted on . Patients with scar-related ventricular tachycardia (VT) who received VT ablation plus a subcutaneous ICD had ...

NEW ORLEANS – The Impella 5.0 and 5.5 left ventricular assist device failed to measure up on outcomes when used for high-risk patients undergoing ventricular tachycardia (VT) ablation therapies, ...

Directing patients selectively to centers performing higher volumes of ventricular tachycardia (VT) ablation may help reduce in-hospital complications following the procedure, an observational study ...

Ablation, a procedure to treat abnormal electrical short circuits caused by a heart attack and is usually reserved for patients who do not improve with medication, may be a better first-line treatment ...

"FULCRUM-VT represents a seminal step forward in advancing ventricular tachycardia management by delivering positive, clinically meaningful results from the first large-scale, rigorously executed ...

LAGUNA HILLS, Calif., March 19, 2026--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment ...

Direct oral anticoagulants (DOACs) bested aspirin for cerebrovascular prevention after left ventricular (LV) arrhythmia ablation, the STROKE-VT trial showed. The anticoagulants eliminated stroke ...

Ventricular tachycardia is a life-threatening heart condition. It occurs when the electrical impulses controlling the heartbeat become erratic, causing the heart to beat too quickly. When this happens ...